News Release

Takeda Pharmaceutical Company Limited
AstraZeneca K.K.
Mitsubishi Tanabe Pharma Corporation
Eisai Co., Ltd.

Helicobacter pylori Gastritis Approved as Additional Indication in Japan for _Helicobacter pylori_ Eradication by Triple Therapy with Proton Pump Inhibitor

Osaka and Tokyo, Japan, February 21, 2013 --- Takeda Pharmaceutical Company Limited (Headquarters: Osaka, President & CEO: Yasuchika Hasegawa), AstraZeneca K.K. (Headquarters: Osaka, President: Paul Hudson), Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, President: Michihiro Tsuchiya), and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) jointly announced today that *Helicobacter pylori* ("*H. pylori*") gastritis has been approved by Japan's Ministry of Health, Labour and Welfare as an additional indication for *H. pylori* eradication by triple therapy with proton pump inhibitors. This therapy consists of a proton pump inhibitor[*1], amoxicillin hydrate[*1], and either clarithromycin[*1] or metronidazole[*1].

H. pylori limited to gastric and d uodenal ulcers, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and the stomach after endoscopic resection of early-stage gastric cancer. Against this backdrop, the respective presidents of the Japanese Society of Gastroenterology, the Japan Gastroenterological Endoscopy Society, and the Japanese Society for Helicobacter Research submitted a joint letter to the Minister of Health, Labour and Welfare in December 2011 requesting the subsequent coverage under NHI of *H. pylori* gastritis as an additional indication for *H. pylori* eradication by triple therapy. In response to this, the four companies submitted a joint application in August 2012 based on the clinical evidence already published to date, together with five other companies

[*2] also seeking additional indication approval for eexpect the approval of th is additional ind
prevention and treatment of diseases related to *H. pylori*.

###

[*1] For a full list of products, please refer to "Notes for Editors" below.

[*2] The joint applicants of the additional indication also include five other companies marketing amoxicillin hydrate, clarithromycin and metronidazole: Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Abbott Japan Co., Ltd., Shionogi & Co., Ltd. and Taisho Pharmaceutical Co., Ltd.
Mylan Inc., Ohara Pharmaceutical Co., Ltd. and Takata Seiyaku Co., Ltd. submitted their respective applications for the additional indication of their drugs in December 2012.

###

Notes for Editors

The approved products included in the application are as follows: (generic name) and <name of manufacturer>

1. Proton Pump Inhibitors

- Takepron® Capsules 15 and 30; Takepron® OD Tablets 15 and 30 (lansoprazole) <Takeda Pharmaceutical Company Limited>
- Omepral® Tablets 10 and 20 (omeprazole) <AstraZeneca K.K.>
- Omeprazon® Tablets 10 mg and 20 mg (omeprazole) <Mitsubishi Tanabe Pharma Corporation>
- Pariet® Tablets 10 mg (rabeprazole sodium) <Eisai Co., Ltd.>
- Nexium® Capsules 10 mg and 20 mg (esomeprazole magnesium hydrate) <AstraZeneca K.K. (sales and distribution by Daiichi Sankyo Co., Ltd.)>
- Omeprazole Tablets "Mylan" 10 mg and 20 mg (omeprazole) <Mylan Inc.>
- Rabeprazole Na Tablets "Ohara" 10 mg (rabeprazole sodium) <Ohara Pharmaceutical Co., Ltd.>

2. Amoxicillin Hydrates

- Pasetocin® Capsules 125 and 250; Pasetocin® Tablets 250 <Kyowa Hakko Kirin Co., Ltd.>
- Sawacillin®Pasetocin4.026Kpe:6 feKR e1(as)-1uek3(.wc)90s6 77(*ek3(.*p)-1uek3(.wc)90s6 77(*e[7sW.59 uek3(.wc)90s6 77 3T4(e)]TJ 0 T et)-3t)-3T4(e)]TJ 0Tj .(aP981